Flying check -in storm again: In the 7 Chinese medicine drinks in Anhui, there are project defects, and 5 rectifications are rectified within a time limit

The flight inspection storm was re -attacking, and the transformation and upgrading of the Chinese patent medicine industry.

On August 17, the Anhui Provincial Drug Administration issued an announcement that seven Chinese medicine drinks (including formula particles) had project defects, of which 5 companies were rectified within a time limit, and 2 companies suspended production, warning, and interviews.

The Jianzhi Bureau sorted out and found that the time of Anhui's flight inspection was concentrated from the end of June to the beginning of July. Among the seven unqualified enterprises, there were 8 general defects in Baohetang (Luzhou) Pharmaceutical Co., Ltd. Industry Co., Ltd., Anhui Jiahe Traditional Chinese Medicine Technology Co., Ltd. each have one serious defect.

It is noticeable that from June 9th to 10th, the Anhui Provincial Drug Administration found 4 general defects in the Tongling Traditional Chinese Medicine Drinking Co., Ltd., Anhui Fengyuan Tongling Traditional Chinese Medicine Drinking Co., Ltd.

Fengyuan Tongling Traditional Chinese Medicine Drink Company is a wholly -owned subsidiary of the listed pharmaceutical company Fengyuan Pharmaceutical. Fengyuan Pharmaceutical is the first pharmaceutical listed company in Anhui Province. The Jianzhi Bureau found that Fengyuan Tongling has been investigated many times because of the unqualified quality of the films, and this time has not been spared.

Although there is no shortcoming of Tongyuan Tongling this time in Anhui, it is clearly required in the treatment measures: corporate rectification.

Traditional Chinese medicine production enterprises are the top priority of flight inspection in the drug supervision system. Based on the results of the national and local flying inspection, although the quality of Chinese medicine drinks (including Chinese medicine particles) has increased year by year, the overall situation is not optimistic.

Multi -violations were investigated

It is not the first time that Fengyuan Tongling's Chinese medicine tablets have been punished at least 6 times before.

In April 2020, the lotus seeds of the lotus seeds produced by Tongyuan Tongling, "[Character], [Examination] Coplinum Eldotrole" project did not meet the standards and was notified by the Anhui Provincial Drug Administration. In addition, Fengyuan Tongling was regulated by Jiangsu Baoying, Shanghai, Huaibei, Anhui, Huobei, Anhui, and Tongling in Anhui in 2019. It was a fine of 1.6 to 2.5 times due to the confiscation of inferior drugs in production and sales.

On June 10, 2019, Ophiopogon and Huoxiang, produced by Tongyuan Tongling, were inspected as inferior drugs inspected by the Shanghai Qingpu Food and Drug Inspection Institute. The amount is 1.2 times fine.

Nearly 4 days later, the non -medicine and powder produced by Tongyuan Tongling were tested by the Suzhou Drug Inspection and Testing Research Center as a bad medicine. The General Administration of Market Supervision of Tongling City in Anhui Province confiscated illegal production of medicines, confiscated illegal income, and the amount of goods at 1.6 times the amount of goods;

On October 21, 2019, Tongyuan Tongling was punished by the General Administration of Market Supervision of Tongling City, Anhui Province. This time, the quality of the Chinese medicine drinking tablets was unqualified. Not only did it confiscate illegal income, but also a fine of 2.5 times the value of the goods.

On December 3, 2019, Tongyuan Tongyuan Tongyuan was confiscated by 12996.5 yuan and a fine of 20,000 yuan by the Baoying County Market Supervision and Administration Bureau of Yangzhou City, Jiangsu Province. In February 2020, Tongyuan Tongling's Chinese medicine was yellow, and it was not tested by drug safety. It was eventually confiscated by the regulatory department and the amount of goods was fined 2.5 times the amount of goods.

Such a bad drinking company, formerly known as a well -known state -owned drinking company, was founded in 1959. In 2003, Fengyuan Group acquired the Tongling Pharmaceutical Corporation as a whole, and this drinking factory also entered Fengyuan Group.

Some analysts pointed out that there have been no series of standard standard systems for Chinese medicine drinks for a long time, so incidents with unqualified product specifications often occur.

Two companies directly discontinued production

In addition to Fengyuan Tongling, the two companies of home and Chinese medicine and Qingchun Tang Pharmaceutical were punished directly, warning, and interviews due to serious defects and did not meet the GMP requirements.

In fact, the Anhui Provincial Pharmaceutical Bureau has issued two announcements in early July that the drug quality management system of home and Chinese medicine and Qingchuntang Pharmaceuticals cannot be effectively operated, and there are hidden risks in the quality and safety of Chinese medicine drinks.

According to relevant regulations, the above two companies should immediately suspend production and clues to illegal and violations found during the inspection. If you are not convinced, a lawsuit can be filed through legal channels.

The suspension of production is the rice bowl of pharmaceutical companies, which means that these two companies have been kicked out of the pharmaceutical circle.

In addition, companies such as Anhui Guangyintang Traditional Chinese Medicine Co., Ltd., Anhui Huifeng National Medicine Co., Ltd., Baohetang (Bozhou) Pharmaceutical Co., Ltd. have also been found to be found out and asked enterprises to rectify.

The round of pharmaceutical supervisors is a layer of control of the Chinese medicine beverage industry to achieve full control of the whole process, and at the same time eliminate some small -scale enterprises. Analysts pointed out that the sales terminals of Chinese medicine drinks are distributed in hospitals or pharmacies. The quality is related to the efficacy of traditional Chinese medicine. It is the bottom line of treating diseases and saving people.

Up to now, the State Drug Administration has established a set of supporting institutional systems to form a new "high -voltage" trend for the supervision of Chinese medicinal materials, Chinese medicine tablets and Chinese medicines.

In February 2020, the State Drug Administration issued the "Special Rectification Work Plan for Traditional Chinese Medicine Drinking Films", which proposed the overall goal and work points for the special rectification work of traditional Chinese medicine drinks. Anhui, Jiangsu, Shandong, Gansu and other places have successively introduced the special rectification work plan for traditional Chinese medicine drinks.

However, if you want to reverse the long -term market barriers of traditional Chinese medicine, the problem of small scattered operators, and the problem of low market concentration, obviously need a long way to go.Data show that the top five Chinese medicine decoction companies have a market share of less than 5%.### ## 曲 霉#

- END -